



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Azilsartan, Azilsartan/Amlodipine besilate, Irbesartan, Irbesartan/Amlodipine besilate, Olmesartan medoxomil, Olmesartan medoxomil/Azelnidipine, Candesartan cilexetil, Valsartan, Valsartan/Amlodipine besilate, and Valsartan/Cilnidipine

June 3, 2014

Non-proprietary Name

- Azilsartan
- Azilsartan/Amlodipine besilate
- Irbesartan
- Irbesartan/Amlodipine besilate
- Olmesartan medoxomil
- Olmesartan medoxomil/Azelnidipine
- Candesartan cilexetil
- Valsartan
- Valsartan/Amlodipine besilate
- Valsartan/Cilnidipine

Safety measure

Precautions section should be revised in the package inserts.

In Precautions for concomitant use subsection of Interactions section, the following texts should be added (underlined parts are revised):

Angiotensin-converting enzyme inhibitors (ACEIs)

Clinical symptoms and measures:

Renal impairment, hyperkalaemia, and/or hypotension may occur. Patients should be carefully monitored for renal function, serum potassium level, and blood pressure.

Mechanism and risk factors:

Concomitant use with ACEIs may increase an effect of renin-angiotensin system blockade.